Rosetta Genomics Ltd. (ROSG) Narrows Q1 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq ends lower as oil prices surge ahead of earnings, economic data
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts ROSG Hot Sheet
Join SI Premium – FREE
Rosetta Genomics Ltd. (NASDAQ: ROSG) reported Q1 non-GAAP loss of ($0.08), $0.14 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $37 thousand versus the consensus estimate of $27 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nurix Therapeutics, Inc. (NRIX) Reports Q3 EPS of $4.73
- Cryo-Cell International, Inc. (CCEL) Tops Q3 EPS by 13c
- PepsiCo shares climb after Q3 beat, though company trims profit forecast
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
